NYSE •
Real Estate •
Real Estate Services •
Quote as of 06/24/2026 15:24
Company Profile
IndustryReal Estate Services
SectorReal Estate
ExchangeNYSE
Market Capitalization132.6 mln
Float31.83 mln
Earnings Date06/10/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.47
Borderline
Relative Strength
100
/ 100
Top performer
Debt / Equity
0.01
Debt-free
ROE
-39.25
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Rafael Holdings is a US-based holding company with investments in healthcare and real estate, focused primarily on developing treatments for cancer and rare genetic diseases. Its most advanced drug candidates include Trappsol Cyclo, targeting a rare and fatal genetic disorder called Niemann-Pick Disease Type C1, and devimistat, an anti-cancer compound, both currently in clinical trials. The company also has interests in surgical device development and owns commercial real estate holdings. Founded in 2017 and based in Newark, New Jersey, Rafael Holdings operates across both the United States and Israel.
